Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules

Comparison of Fenofibric Acid Bioavailability From 45 mg and 135 mg Strength ABT-335 Capsules

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00839293

Enrollment

Registered

2009-02-09

Start date

2009-02-28

Completion date

Unknown

Last updated

2010-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Bioavailability

Brief summary

The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335.

Interventions

DRUGABT-335

Once, see arm description for more information

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* A condition of general good health * BMI 18 to 29

Exclusion criteria

* Currently enrolled in another clinical study * Females who are pregnant or breast-feeding

Design outcomes

Primary

Measure	Time frame
To determine the bioavailability of ABT-335 in healthy subjects as measured by timed pharmacokinetic blood draws from pre-dose (0 hour) to 120 hours post dose	14 Days
To evaluate the safety and tolerability of ABT-335 in healthy adults after single dosage	14 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026